Emergent BioSolutions is facing increased competition and pricing pressure in the naloxone market while undergoing restructuring and accelerating government deliveries.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Emergent BioSolutions is facing increased competition and pricing pressure in the naloxone market while undergoing restructuring and accelerating government deliveries.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Emergent BioSolutions
multinational biopharmaceutical company headquartered in Gaithersburg, Maryland, USA